Posted Oct 17 , 2019 04:08 AM
Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches into Diabetes Management.
Fritzen K, et al. Journal of Diabetes Science and Technology 2019:Online_1-11
Institute Summary (excerpted from the abstract):
Self-monitoring of blood glucose supported by the diabetes-app OneTouch Reveal® has demonstrated to improve HbA1c. We aimed at analyzing costs savings related the integration of telemedical features into diabetes management. Data from a randomized controlled trial were used to assess the 10-year risk of patients for fatal myocardial infarction (MI). On the basis of this risk assessments—also related to a 5% or 10% reduction of hypoglycemic episodes—cost savings for the health care systems of five European countries—France, Germany, Italy, Spain, and the United Kingdom— were modeled. HbA1c reduction of 0.92% in insulin-treated type 2 diabetes patients (T2DM) was associated with a 2.3% decreased 10-year risk for fatal MI. In combination with a 10% reduction of hypoglycemic events this risk reduction led to cost savings of €16.1 million (France), €57.8 million (Germany), €30.9 million (Italy), €23.8 million (Spain), and €5.8 million (UK), considering all insulin-treated T2DM patients in the respective countries.
Why is this important?
In 2017 health care expenditures due to diabetes in Europe were $166 billion—growing constantly, attributed mostly to diabetes-related complications. Utilization of telemedicine, a combination of telecommunication and medical devices, together with usual care can facilitate the timely management of diabetes through sharing real life data, leading to an improvement in SMBG and optimization of HbA1c. A previous publication showing the benefit of blood glucose meters with color range indicators (CRI) showed significant improvement in glycemic control in both patients with type 1 and type 2 diabetes (T1DM and T2DM). This publication adds to that the value of both the meter and the software (Reveal) to potentially improve the outcomes of several diabetes complications and thus reduce the costs in such patients. This paper uses a standard model of glucose control costs and benefits to validate such a process in patients with diabetes across many countries suggesting significant cost savings with the use of this system. Improving metabolic control and thus risk for comorbidities like MI by combining the glucose meter with CRI with telemedical features has the potential to reduce costs for European health care systems for insulin using patients with type 2 diabetes. Are you using a meter/software system with your patients who have diabetes? Have you seen benefits in your patients’ glucose control and in the patients and providers understanding of glucose values using that software?
Concluding Thought: “We’re seeing an interesting convergence of technology, medicine, social issues and human progress.” - John Nosta
Read the Abstract: